Kazia Therapeutics Expands Paxalisib Clinical Trial into HR+/HER2- Breast Cancer, Supported by Preclinical Data Showing Strong Clinical Activity and Safety in HR+ Breast Cancer

Trial StartPaxalisibFulvestrantPalbociclibPositive

AI Analysis

Summary

Kazia Therapeutics announced an expansion of its paxalisib clinical trial into HR+/HER2- breast cancer, with a three-arm expansion of the ongoing TNBC trial evaluating paxalisib plus fulvestrant, with and without palbociclib. Preclinical data demonstrate the combination is well tolerated with statistically significant antitumor activity.

Clinical Trial Data

Outcome Details

Preclinical data show paxalisib combined with standard-of-care therapy is well tolerated and produces statistically significant antitumor activity

Importance:6/10

Sentiment:

0.70

oncologybreast cancerclinical trial expansionpreclinical datacombination therapy

Related Companies

$KZIA

Read the original article

Published by PR Newswire Biotech on September 1, 2026 11:15 AM

Read Original